Ionis Pharmaceuticals (IONS) Capital Expenditures (2009 - 2026)

Ionis Pharmaceuticals' Capital Expenditures history runs 18 years deep, the most recent figure standing at $21.8 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 73.04% year-over-year to $21.8 million; the TTM figure through Mar 2026 stood at $60.6 million (up 13.62% YoY), while the FY2025 annual figure was $51.4 million, up 13.61% from the prior year.
• Capital Expenditures was $21.8 million for Q1 2026 at Ionis Pharmaceuticals, up from $21.3 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $25.5 million in Q4 2024 to a low of -$24.5 million in Q4 2023.
• Historically, Capital Expenditures has averaged $7.9 million across 5 years, with a median of $6.2 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Capital Expenditures plunged 690.77% in 2023, then jumped 322.98% in 2024.
• A 5-year view of Capital Expenditures shows it stood at $4.1 million in 2022, then slumped by 690.77% to -$24.5 million in 2023, then jumped by 204.27% to $25.5 million in 2024, then decreased by 16.49% to $21.3 million in 2025, then grew by 2.21% to $21.8 million in 2026.
• The last three Capital Expenditures figures came in at $21.8 million (Q1 2026), $21.3 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.